QuantaBio

Executive Summary

QuantaBio is a leading U.S.-based supplier of high-performance reagents and kits for nucleic acid amplification, detection, and next-generation sequencing (NGS) library preparation. Founded in 2005 and headquartered in Beverly, Massachusetts, the company specializes in its proprietary 'ToughMix' formulations, which are engineered to process difficult sample types such as blood, soil, and plants without extensive purification. This unique capability positions QuantaBio as a key enabler in life science research, drug discovery, and public health diagnostics, where sample quality often limits throughput and accuracy. The company's product portfolio spans PCR, qPCR, and NGS library preparation, serving academic, government, and biopharma customers globally. With no disclosed funding or valuation, QuantaBio operates as a private, self-funded entity, likely with steady revenue from consumable sales. Its technology addresses a critical pain point in molecular biology, reducing workflow complexity for challenging samples. As demand grows for decentralized diagnostics and field-deployable assays, QuantaBio's robust reagents are well-positioned to capture market share. Upcoming catalysts include new product launches, strategic partnerships, and potential expansion into clinical diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Launch of ToughMix for direct PCR from liquid biopsy samples80% success
• 2026Strategic partnership with a major NGS platform provider70% success
• 2027CE-IVD marking of ToughMix kits for clinical diagnostics60% success